|
| Status |
Public on Jun 04, 2018 |
| Title |
RNA-sequencing of shSRC-1 and shNT tamoxifen treated LY2 cells |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
The steroid co-activator protein SRC-1 plays an important role in endocrine therapy resistant breast cancer. Its expression is associated with large high grade tumours, HER2 positivity, disease recurrence and resistance to endocrine therapy. SRC-1's role in affecting the transcriptome of the breast cancer endocrine resistant setting is uncovered through this RNA-seq analysis of LY2 cells grown with or without the presence of SRC-1
|
| |
|
| Overall design |
We report the RNA-sequencing of tamoxifen treated LY2 breast cancer cells treated with non-targeting shRNA or SRC-1 (NCOA1) targeting shRNA and examine the gene expression differences.
|
| |
|
| Contributor(s) |
Young LS, Fagan A, Ward E |
| Citation(s) |
29567811 |
| Submission date |
Jun 04, 2017 |
| Last update date |
May 15, 2019 |
| Contact name |
Leonie Young |
| Organization name |
Royal College of Surgeons, Ireland
|
| Department |
Surgery
|
| Lab |
Endocrine Oncology Research Group
|
| Street address |
York Street
|
| City |
Dublin |
| ZIP/Postal code |
Dublin 2 |
| Country |
Ireland |
| |
|
| Platforms (1) |
| GPL11154 |
Illumina HiSeq 2000 (Homo sapiens) |
|
| Samples (8)
|
|
| This SubSeries is part of SuperSeries: |
| GSE99649 |
RNA-sequencing and MeDIP-sequencing of shSRC-1 and shNT tamoxifen treated LY2 cells |
|
| Relations |
| BioProject |
PRJNA389214 |
| SRA |
SRP108577 |
Less...
More...